Updated analyses of the international, open-label, randomized, phase 3 alcanza study: Longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL) Meeting Abstract
| Authors: | Horwitz, S. M.; Scarisbrick, J. J.; Dummer, R.; Duvic, M.; Kim, Y. H.; Walewski, J.; Whittaker, S.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; Eradat, H.; Sanches, J. A.; Ortiz-Romero, P. L.; Akilov, O. E.; Trotman, J.; Taylor, K.; Dalle, S.; Weichenthal, M.; Fisher, D. C.; Stadler, R.; Feldman, T. A.; Kuzel, T. M.; Gru, A. A.; Wang, Y.; Palanca-Wessels, M. C.; Lin, H. M.; Liu, Y.; Little, M.; Prince, H. M. |
| Abstract Title: | Updated analyses of the international, open-label, randomized, phase 3 alcanza study: Longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL) |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419403333 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.1509.1509 |
| Notes: | Meeting Abstract: 1509 -- Source: Wos |
